SMLR · Semler Scientific, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.49M | $8.22M | $8.84M | - | $16.32M | $14.46M | $15.90M | - | $16.32M | $14.83M |
| Cost of Revenue | $636.0K | $739.0K | $937.0K | - | $1.16M | $1.25M | $1.25M | - | $1.11M | $1.22M |
| Gross Profit | $6.86M | $7.48M | $7.90M | - | $15.16M | $13.21M | $14.66M | - | $15.21M | $13.61M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $8.01M | $5.14M | $4.89M | - | $3.13M | $2.96M | $2.87M | - | $3.71M | $3.46M |
| Total Operating Expenses | $12.88M | $10.27M | $39.94M | - | $8.45M | $9.12M | $8.93M | - | $10.02M | $11.43M |
| D&A | - | - | $120.0K | - | - | - | $176.0K | - | - | - |
| Operating Income | ($5.39M) | ($2.05M) | ($31.10M) | - | $5.07M | $5.35M | $6.98M | - | $6.30M | $7.18M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $6.90M | $13.63M | ($10.17M) | - | $766.0K | $1.13M | $1.72M | - | $1.47M | $1.79M |
| Net Income | $16.90M | $66.93M | ($64.70M) | - | $5.61M | $11.0K | $6.07M | - | $5.51M | $5.88M |
| EPS - Basic | $1.14 | $5.71 | ($6.74) | - | $0.80 | $0.00 | $0.88 | - | $0.82 | $0.88 |
| EPS - Diluted | $1.07 | $5.04 | ($6.74) | - | $0.72 | $0.00 | $0.78 | - | $0.71 | $0.75 |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.18M | $13.48M | $9.74M | $8.82M | $6.57M | $7.33M | $62.75M | $57.20M | $37.50M | $39.49M |
| Accounts Receivable | $2.56M | $2.83M | $3.14M | $4.38M | $6.67M | $7.47M | $6.13M | $6.13M | $5.97M | $6.03M |
| Inventory | $485.0K | $558.0K | $370.0K | $358.0K | $380.0K | $385.0K | $408.0K | $445.0K | $439.0K | $476.0K |
| Accounts Payable | $200.0K | $156.0K | $590.0K | $140.0K | $545.0K | $227.0K | $410.0K | $402.0K | $300.0K | $509.0K |
| Current Assets | $53.51M | $21.90M | $18.45M | $22.69M | $21.49M | $23.69M | $71.91M | $65.94M | $64.38M | $60.75M |
| Total Assets | $596.68M | $522.60M | $293.44M | $239.83M | $92.19M | $84.79M | $83.86M | $78.06M | $79.44M | $75.46M |
| Current Liabilities | $27.22M | $36.77M | $35.67M | $6.31M | $6.84M | $6.36M | $5.90M | $6.20M | $8.58M | $10.08M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $459.75M | $383.41M | $161.68M | $230.75M | $85.36M | $78.40M | $77.91M | $71.80M | $70.77M | $65.26M |
| Retained Earnings | $119.83M | $102.93M | $36.00M | $100.70M | $71.50M | $65.89M | $65.88M | $59.80M | $55.58M | $50.07M |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.91M) | - | - | - | $5.62M | - | - | - |
| Investing Cash Flow | - | - | ($87.31M) | - | - | - | ($81.0K) | - | - | - |
| Financing Cash Flow | - | - | $90.14M | - | - | - | $11.0K | - | - | - |
| CapEx | - | - | - | - | - | - | $4.0K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | $5.62M | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 91.5% | 91.0% | 89.4% | - | 92.9% | 91.3% | 92.2% | - | 93.2% | 91.8% |
| Operating margin | -72.0% | -25.0% | -352.0% | - | 31.0% | 37.0% | 43.9% | - | 38.6% | 48.4% |
| EBITDA margin | - | - | -350.7% | - | - | - | 45.0% | - | - | - |
| Net margin | 225.6% | 814.6% | -732.3% | - | 34.4% | 0.1% | 38.2% | - | 33.8% | 39.6% |
| Free cash flow margin | - | - | - | - | - | - | 35.3% | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 0.93 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 107.0% | 62.6% | 55.4% | - | 19.2% | 20.5% | 18.0% | - | 22.7% | 23.3% |
| Effective tax rate | 29.0% | 16.9% | - | - | 12.0% | 99.0% | 22.1% | - | 21.1% | 23.3% |
| Return on assets | 2.8% | 12.8% | -22.0% | - | 6.1% | 0.0% | 7.2% | - | 6.9% | 7.8% |
| Return on equity | 3.7% | 17.5% | -40.0% | - | 6.6% | 0.0% | 7.8% | - | 7.8% | 9.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.97 | 0.60 | 0.52 | 3.59 | 3.14 | 3.72 | 12.18 | 10.64 | 7.51 | 6.03 |
| Quick ratio | 1.95 | 0.58 | 0.51 | 3.54 | 3.09 | 3.66 | 12.11 | 10.56 | 7.45 | 5.98 |
| Cash ratio | 0.37 | 0.37 | 0.27 | 1.40 | 0.96 | 1.15 | 10.63 | 9.23 | 4.37 | 3.92 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.30 | 1.36 | 1.81 | 1.04 | 1.08 | 1.08 | 1.08 | 1.09 | 1.12 | 1.16 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.02 | 0.03 | - | 0.18 | 0.17 | 0.19 | - | 0.21 | 0.20 |
| Inventory turnover | 1.31 | 1.32 | 2.53 | - | 3.04 | 3.26 | 3.06 | - | 2.53 | 2.56 |
| Days sales outstanding | 125d | 126d | 130d | - | 149d | 188d | 141d | - | 133d | 148d |
| Days inventory outstanding | 278d | 276d | 144d | - | 120d | 112d | 119d | - | 144d | 143d |
| Days payable outstanding | 115d | 77d | 230d | - | 172d | 66d | 120d | - | 99d | 152d |
| Cash conversion cycle | 288d | 324d | 44d | - | 97d | 234d | 140d | - | 179d | 139d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -54.1% | -43.2% | -44.4% | - | 0.0% | -2.4% | -12.6% | - | 16.2% | 0.0% |
| Revenue CAGR (3y) | -18.9% | -17.9% | -14.3% | - | 5.3% | 0.4% | 6.5% | - | 15.0% | 32.5% |
| Revenue CAGR (5y) | -6.9% | 5.2% | -1.3% | - | 12.9% | 12.7% | 18.7% | - | 23.9% | 22.0% |
| Gross profit growth (YoY) | -54.8% | -43.4% | -46.1% | - | -0.3% | -2.9% | -13.5% | - | 17.8% | -1.8% |
| Operating income growth (YoY) | - | - | - | - | -19.6% | -25.5% | 11.5% | - | 41.0% | 38.7% |
| Net income growth (YoY) | 201.3% | 608381.8% | - | - | 1.7% | -99.8% | 22.2% | - | 50.0% | 44.3% |
| EPS growth (YoY) | 48.6% | - | - | - | 1.4% | - | 23.8% | - | 54.3% | 47.1% |
| EPS CAGR (3y) | 32.5% | 114.6% | - | - | 12.2% | - | 9.1% | - | 5.2% | 79.4% |
| EPS CAGR (5y) | 11.9% | 107.8% | - | - | -5.6% | - | 27.7% | - | - | 31.6% |
| FCF growth (YoY) | - | - | - | - | - | - | 633.7% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 438.6% | 389.1% | 107.5% | 221.4% | 20.6% | 20.1% | 27.3% | 29.0% | 35.2% | 28.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$56.29M totalSingle Reportable Segment$56.29M · 100.0%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Semler Scientific against the 5 most active filers in the same SIC group.